Sonexa Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sonexa Therapeutics, Inc. - overview
Established
2007
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2007 and California, US, Sonexa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops drug treatments and therapeutics for Alzheimer's disease and related disorders. The company's product ST101, an active molecule compound which is small and orally taken, penetrates through the blood-brain-barrier and restores learning and memory capability throughout animal models of cognitive impairment relevant to Alzheimer's.
Current Investors
Alta Partners, Domain Associates, Scale Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.sonexa.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.